Hepion Pharmaceuticals

Leadership team

Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. (Pres, CEO & Director)

Mr. John T. Cavan (Chief Financial Officer)

Dr. Todd M. Hobbs M.D. (Chief Medical Officer)

Products/ Services

Biotechnology, Life Science, Medical, Pharmaceutical, Service Industry

Headquarters

Edison, New Jersey, United States

Established

2013

Company Registration

SEC CIK number: 0001583771

Social Media

URL

https://www.hepionpharma.com

Overview

Location

Recognition and Award

References

Summary

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

History

Hepion Pharmaceuticals was founded in 2017 with a mission to develop treatments for liver diseases. The company's founders have extensive experience in biopharmaceuticals, drug discovery, and clinical development. The company is located in San Diego, California and has a team of scientists and researchers working to develop innovative treatments.

Mission

The mission of Hepion Pharmaceuticals is to develop and commercialize innovative treatments to improve the lives of patients with liver diseases.

Vision

Our vision is to become the global leader in NASH treatment research and development.

Key Team

Dr. John Z. Sullivan-Bolyai (Part-Time Consultant)

Dr. Launa J. Aspeslet Ph.D. (Chief Operating Officer)

Dr. Patrick R. Mayo Ph.D. (Sr. VP of Clinical Pharmacology)

Dr. Daren Ure Ph.D. (Chief Scientific Officer)

Sharen Pyatetskaya (Director of Investor Relations)

Dr. Stephen A. Harrison M.D. (Member of Scientific Advisory Board & Consultant Medical Director)

Dr. Daniel J. Trepanier Ph.D. (Sr. VP of Drug Devel.)

Recognition and Awards

Hepion Pharmaceuticals has been recognized for its innovations and contributions to the field of drug development, receiving multiple awards from organizations such as the American Association for the Study of Liver Diseases and the Society for Biomolecular Sciences . As of 2021, the company has been awarded seven different awards for its work in the field of NASH research and drug development.